Financials (USD)
Sales 2024 * | 139M | Sales 2025 * | 166M | Capitalization | 467M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | -4M | EV / Sales 2024 * | 3.37 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.82 x |
P/E ratio 2024 * |
-28.6
x | P/E ratio 2025 * |
-118
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Peregrine Pharmaceuticals
Managers | Title | Age | Since |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 20-07-29 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 18-07-31 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 17-11-26 |
Joseph Carleone
CHM | Chairman | 78 | 17-11-26 |
Catherine Mackey
BRD | Director/Board Member | 68 | 19-07-24 |
1st Jan change | Capi. | |
---|---|---|
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |